Abstract Aims/hypothesis To set up a clinical trial to establish whether nicotinamide can prevent or delay clinical onset of Type 1 diabetes.
insulin response in the IVGTT was below the 10 th centile in 34%. Additional islet autoantibodies were identified in 354 trial entrants. Diabetes-associated HLA class II haplotypes were found in 84% of the younger age group and 80% of the older group. The protective haplotype HLA-DQA1*0102-DQB1*0602 was found in 10% overall. Europe includes countries with the highest incidence of Type 1 (insulin-dependent) diabetes mellitus in the world. These rates continue to rise rapidly, and the EURODIAB TIGER Concerted
Conclusions/interpretation
Action has shown an annual 3 to 4% increase in the incidence of childhood diabetes across our continent [1] . In Finland, it is estimated that childhood diabetes is now four times as common as it was in the 1950s [2] . There is currently no means of preventing or curing this disorder. Type 1 diabetes can, however, be predicted by screening for islet autoantibodies, and both animal and human pilot studies suggest that prevention is possible. The US Diabetes Prevention Trial-Type 1 (DPT-1) has recently reported experience with parenteral insulin therapy in high risk relatives of an individual with Type 1 diabetes [3] . Here we show baseline data from a trial of high-dose
oral nicotinamide, and demonstrate that a candidate preventive measure can be tested successfully on a multinational collaborative basis.
Methods
Study Design ENDIT is a randomised, double-blind, placebo controlled trial designed to test whether daily oral administration of high dose nicotinamide can produce a clinically useful reduction in the rate of progression to Type 1 diabetes in relatives at increased risk of contracting the disease.
The null hypothesis is that nicotinamide at a dose of 1.2 g/m 2 cannot achieve a 35 to 40% reduction in the rate of progression to Type 1 diabetes over a five year period. The study is designed to have 90% power to detect such a difference at the 5% significance level, based on the assumption that non-diabetic first-degree relatives under the age of 40 with confirmed levels of islet cell antibodies (ICA) greater than or equal to 20 JDF units have more than 40% risk of insulin therapy within 5
years. Sample size calculations showed that a minimum of 211 in each group would be needed to achieve this.
Inclusion Criteria First-degree relatives of patients who developed Type 1 diabetes before age 20, and who were themselves aged between 3 and 40 years, were eligible for screening. At the start of the study, the upper age limit for inclusion was 60 years, but this was lowered in 1995 following a multicentre analysis which showed that the risk associated with ICA in relatives above age 40 was low [4] . Family members over age 40 who had already been recruited and screened received an explanation of this revised risk estimate but were allowed to proceed to randomisation if they so wished.
Study organisation Study co-ordination and data management were carried out centrally.
Participants have been identified via 354 local centres in 20 countries in Europe, Canada and the USA (Table 1) . Participation in each country is organised through one to two national co-ordinators, who are responsible for all communications with local centres and for ensuring local compliance with the protocol. The protocol was approved by the research ethics committee or equivalent in each participating centre, and also by the appropriate national drug regulatory authorities. Written informed consent was obtained from all participants.
[ Exclusion criteria Individuals with any chronic disease likely to affect outcome, toxicity or compliance, women who were breast feeding, pregnant or of child bearing age and not using effective contraception, and anyone taking vitamin preparations containing nicotinamide were excluded from the study. Those found to have diabetes on oral glucose tolerance testing were also excluded.
Oral glucose tolerance test (OGTT)
Oral glucose (1.75 g/kg body weight, up to a maximum of 75 g) was administered following an overnight fast. Venous plasma samples collected at 0 and 120 minutes were tested for glucose in the local study centre laboratory, and diabetes and impaired glucose tolerance were defined using WHO criteria [5] .
Intravenous glucose tolerance test (IVGTT)
IVGTTs were carried out according to the ICARUS protocol [6] . A glucose dose of 0.5 g/kg, up to a maximum of 35 g, was infused over 3 min±15 s, and blood samples collected at −5, 0, 1, 3, 5 and 10 min. First phase insulin response was calculated as the sum of the insulin levels at +1 and +3 min.
Islet cell antibodies
The initial ICA assay in all or most samples was carried out in local laboratories in ten countries (Table 1) , and all ICA testing was done in the central laboratory for the remainder.
Samples found to have ICA greater than or equal to 5 JDF units in local laboratories were sent to the central laboratory for confirmation. All local laboratories participated in a sample exchange and workshop programme to ensure that assay sensitivity was maintained throughout the period of screening, but study entry was based solely upon results from the central laboratory.
ICA determination in the central laboratory was performed by indirect immunofluorescence [7] . Briefly, sera were incubated on sections of human pancreas for 30 min at room temperature.
After washing, bound antibody was revealed using a sheep anti-human immunoglobulin (GAM)
FITC conjugate (TBS, Birmingham, UK). The sections were examined in a blinded fashion under a fluorescence microscope (Leica, Wetzlar, Germany) by two observers. All samples were initially assayed at a 1 in 2 dilution and assigned an arbitrary intensity score from 0 to 7. Samples with an intensity score of 1 or greater were re-assayed in a quantification assay [8] , while those samples with an intensity score of less than 1 were considered negative. Five standards and two internal controls were included in each assay. Overall assay performance was monitored by the inclusion of 3 coded "external" quality control samples in every 100 samples assayed and the inter assay co-efficient of variation (CV) of the ICA assay was 51% at 14 JDF units, 35% at 38 JDF units and 22% at 60 JDF units. The ICA assay achieved 81% sensitivity with 86% specificity in the First
Immunology of Diabetes Society (IDS) Combined Antibody Workshop [9] . A number of pancreas substrates were used during the course of the study. To maintain consistency, each new substrate was evaluated in parallel with the old substrate by measuring ICA on a panel of 140 samples.
GAD and IA-2 ic autoantibodies
Autoantibodies to GAD and IA-2 ic were measured in radiobinding assays in the Division of Medicine, University of Bristol, UK [10] , and considered positive if above the 97.5 th centile of a control population of 2860 schoolchildren. The GAD antibody assay achieved 91% sensitivity with 99% specificity, and the IA-2 antibody assay achieved 74% sensitivity with 99% specificity in the first Immunology of Diabetes Society (IDS) combined antibody workshop [9] .
Insulin autoantibodies Samples were assayed for insulin autoantibodies in the Division of Medicine, University of Bristol, UK [11] , using a format similar to that used for measuring GAD and IA-2
antibodies. Immune complexes were isolated using protein A sepharose. Bound counts for each sample were calculated after subtraction of background counts, and results were expressed in arbitrary units derived from a standard curve. Sera with insulin binding above 0.4 units were tested in a competition assay in which each sample was incubated with label in the presence of excess unlabelled insulin (Humulin, Lilly, Basingstoke, Hants, UK). Specific bound counts were converted into arbitrary units as described above. Samples assayed for insulin autoantibodies were considered positive if they had levels above the 97.5 th centile of the schoolchildren. The assay achieved 58% sensitivity with 99% specificity on the samples included in the First IDS Combined Antibody Workshop [9] .
Insulin assay Plasma insulin was measured in a single laboratory at the Steno Diabetes Centre, Gentofte, Denmark using an enzyme-linked two-site immunoassay [12] . The method uses two murine monoclonal antibodies that bind to different epitopes on the insulin molecule and shows a less than 1% cross-reactivity with intact human proinsulin. During the course of the study, kits produced by two manufacturers (ELISA, Dako, Ely, UK) and (Autodelfia, Wallac Oy, Turku, Finland) were used for insulin measurement. The kits were based on the same immunochemistry and detailed method comparison showed results obtained by both methods to be essentially identical.
To allow comparison of IVGTT results with FPIR centiles obtained in the University of Washington, Seattle and used for DPT-1, 105 samples spanning the range 0-500 pmol/l were assayed in both laboratories. The regression equation of insulin concentration measured in Seattle on the insulin concentration measured in the Steno laboratory was used to derive a correction factor to standardise the measurement to the Seattle assay [13] .
HLA genotyping HLA genotyping was carried out in the Institute of Transplantation Immunology, National Hospital, Oslo, Norway. Typing of HLA-DQA1, -DQB1 and -DRB1*04 subtypes were mainly done using PCR-SSO [14] . A few samples were also typed for DQA1, DQB1 and/or DRB1*04 subtypes with an allele specific PCR kit (Olerup SSP Genovision, Oslo, Norway) and/or with a reverse dot-blot kit (Reli-SSOP, Dynal, Oslo, Norway).
Results
First-degree relatives were screened from 20 countries (Table 1) . Initial ICA testing on approximately 16 000 samples was carried out in local laboratories and 3402 of these were sent to the central laboratory for confirmation of ICA positivity, while samples from a further 13 718 relatives were first tested for ICA in the central laboratory. Approximately 16% of those tested were above age 40 when the first screening sample was collected.
A total of 1004 individuals fulfilled the ICA criteria for eligibility of whom 552 were randomised.
The reasons for non-randomisation of the remainder are shown in Fig. 1 . Nationality is shown in Table 1 and other subject characteristics are shown in Table 2 . Of 552 relatives randomised, 331 were below age 20 years and 221 aged more than 20. In the younger age group 87% were siblings of a diabetic proband and 13% were offspring. In the older age group 21% were siblings, 76% were parents and 3% were offspring.
[ 
Discussion
The prodromal phase preceding the onset of Type 1 diabetes is characterised by progressive beta-cell destruction and the appearance of circulating islet autoantibody markers, thus providing an opportunity for intervention to halt or delay the disease process. Prophylaxis of diabetes has been achieved, sometimes with lasting protection, using a variety of interventions in two animal models of spontaneous autoimmune diabetes, the NOD mouse and the BB rat. Early human studies of immune intervention concentrated on the attempt to prolong beta-cell function in recently diagnosed patients requiring insulin therapy. Prospective randomised placebo controlled double-blind studies showed, for example, that Cyclosporin A can protect beta-cell function to the extent that some 25% of patients on Cyclosporin were able to control their diabetes on diet alone one year after diagnosis, as against 5 to 10% of controls [15, 16] . Unfortunately this benefit does not persist, and the high rate of complications has limited this approach to therapy. Since the great majority of beta-cells seem to have been destroyed by the time of clinical presentation, it seems reasonable to conclude that earlier intervention, at a stage when the beta-cell mass is relatively intact, could produce a more lasting benefit. is thought to be mediated by this pathway [18, 19, 20, 21] , but it could differ in its effects upon human beta cells [22] . Previous trials in high risk individuals have reached conflicting conclusions [23, 24] .
Nicotinamide is the amide of nicotinic acid; both are components of vitamin B3. Although their action as anti-pellagra vitamins is similar, their metabolic effects are quite different. In particular, nicotinic acid has clinical uses as a vasodilator and lipid lowering agent, and induces insulin resistance. These effects are not seen to any significant extent with nicotinamide, and insulin secretion is unaffected [25] although it has also been reported to induce a milder degree of insulin resistance [26] . Nicotinamide is water-soluble, and readily absorbed by mouth. Pharmacokinetic studies carried out by our group have shown that human metabolism is predominantly by methylation to N-methyl-2-pyridone-5-carboxamide, in which form it is excreted in the urine; oxidation to nicotinamide oxide also occurs, but there is no direct conversion to nicotinic acid [27, 28] . At high doses, such as those used in ENDIT, peak levels of nicotinamide of 0.3-1.0 mmol/l are seen in the circulation; the 50% inhibition concentration of nicotinamide for PARP is about 0.1 mmol/l [29] . The safety profile of high dose nicotinamide has been reviewed, and the ratio of risk to benefit would be highly favourable if efficacy can be shown [30] .
First-degree relatives of a child with Type 1 diabetes are at increased risk of progression to the disease, and are highly motivated to participate in such studies; it is therefore logical to offer intervention to people in this category. Although now largely superseded by measurement of other autoantibodies, ICA for many years formed the basis of diabetes prediction, and were used to identify high risk of progression in ENDIT, as in current US studies of intervention in pre-type 1 diabetes [3] . Family studies have shown that 2 to 2.5% of siblings and parents of a child with diabetes have ICA greater than or equal to 20 JDF units, and that 40% of those aged less than 40 years will progress to insulin treatment within 5 years of first detection. This risk is increased if additional autoantibodies to GAD, IA-2 or insulin are detected [31, 32] , or if first phase insulin secretion is impaired [4] .
The US Diabetes Prevention Trial-Type 1 (DPT-1) started shortly after ENDIT and has screened more than 70 000 first-degree relatives for ICA. The results of intervention using parental insulin have recently been reported [3] , and a second trial using oral insulin is in progress. These studies require very large-scale participation, and in Europe are most logically done on a multinational basis. For this reason simple robust entry criteria were selected for ENDIT, and the IVGTT was not used as a randomisation criterion. The parenteral arm of DPT-1 required an FPIR below 10% of a control population, and 37% of ENDIT participants would have fallen into this category. Since DPT-1 selected individuals with a low insulin response, it is not surprising that 33% had evidence of metabolic decompensation in the form of impaired glucose tolerance, as against 9% of those in ENDIT.
When ENDIT was planned (the study began in 1994), risk assessment by means of autoantibodies other than ICA had not been validated. Since then it has been shown that primary screening for autoantibodies against biochemically defined islet antigens has the potential to provide an enriched sample for future intervention trials [33] . In the light of present knowledge we would now have excluded the 198 ENDIT participants who had ICA without other islet autoantibodies, and we have confirmed a lower rate of IGT and low FPIR in this group. Other intervention studies have also excluded patients carrying the protective haplotype HLA-DQA1*0102-DQB1*0602 (DQ6) [3] . Within ENDIT, however, of 50 individuals with DQ6, 26 had ICA alone but the remainder had more than one autoantibody; nine had all four. In addition the frequency of both low FPIR and IGT in the subgroup with DQ6 were similar to those in the individuals who did not carry this haplotype. Further study will be needed to establish which individuals with DQ6 should be excluded from future intervention trials. (14) 73 (24) DQ2/DQ8
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